Weiss Ratings reissued their sell (e+) rating on shares of 23andMe (NASDAQ:ME - Free Report) in a research note released on Wednesday morning,Weiss Ratings reports.
23andMe Price Performance
23andMe stock traded down $0.32 during midday trading on Wednesday, hitting $2.42. The company's stock had a trading volume of 368,496 shares, compared to its average volume of 216,476. The company has a market cap of $64.93 million, a price-to-earnings ratio of -0.16 and a beta of 1.14. 23andMe has a 1-year low of $2.42 and a 1-year high of $13.74. The company has a 50-day moving average price of $3.20 and a two-hundred day moving average price of $4.65.
23andMe (NASDAQ:ME - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of ME. Shay Capital LLC lifted its stake in 23andMe by 71.7% in the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company's stock valued at $2,283,000 after purchasing an additional 293,358 shares during the last quarter. Virtu Financial LLC purchased a new position in 23andMe in the 4th quarter worth $49,000. Leavell Investment Management Inc. bought a new position in 23andMe during the 4th quarter worth approximately $32,000. MassMutual Private Wealth & Trust FSB purchased a new position in shares of 23andMe in the fourth quarter worth $40,000. Finally, FNY Investment Advisers LLC purchased a new position in 23andMe during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 36.10% of the company's stock.
About 23andMe
(
Get Free Report)
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Featured Articles
Before you consider 23andMe, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 23andMe wasn't on the list.
While 23andMe currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
